- Home
- SNTI vs PROV Comparison
SNTI vs PROV Comparison
Compare SNTI & PROV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- PROV
- Stock Information
- Founded
- SNTI 2016
- PROV 1956
- Country
- SNTI United States
- PROV United States
- Employees
- SNTI N/A
- PROV N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- PROV Savings Institutions
- Sector
- SNTI Health Care
- PROV Finance
- Exchange
- SNTI Nasdaq
- PROV Nasdaq
- Market Cap
- SNTI 85.3M
- PROV 100.7M
- IPO Year
- SNTI N/A
- PROV 1996
- Fundamental
- Price
- SNTI $2.26
- PROV $15.61
- Analyst Decision
- SNTI Strong Buy
- PROV Hold
- Analyst Count
- SNTI 2
- PROV 1
- Target Price
- SNTI $8.50
- PROV $16.00
- AVG Volume (30 Days)
- SNTI 385.8K
- PROV 6.5K
- Earning Date
- SNTI 08-12-2025
- PROV 07-28-2025
- Dividend Yield
- SNTI N/A
- PROV 3.59%
- EPS Growth
- SNTI N/A
- PROV N/A
- EPS
- SNTI N/A
- PROV 0.97
- Revenue
- SNTI N/A
- PROV $39,909,000.00
- Revenue This Year
- SNTI N/A
- PROV $3.06
- Revenue Next Year
- SNTI $150.00
- PROV $9.15
- P/E Ratio
- SNTI N/A
- PROV $16.08
- Revenue Growth
- SNTI N/A
- PROV 1.24
- 52 Week Low
- SNTI $1.52
- PROV $12.01
- 52 Week High
- SNTI $16.94
- PROV $16.70
- Technical
- Relative Strength Index (RSI)
- SNTI 37.88
- PROV 53.89
- Support Level
- SNTI $2.05
- PROV $15.39
- Resistance Level
- SNTI $2.35
- PROV $15.90
- Average True Range (ATR)
- SNTI 0.30
- PROV 0.37
- MACD
- SNTI 0.00
- PROV 0.00
- Stochastic Oscillator
- SNTI 20.00
- PROV 66.30
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About PROV Provident Financial Holdings Inc.
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. Through the bank, it is engaged in providing community and mortgage banking services to consumers and small to mid-sized businesses in the Inland Empire region of Southern California. The company's business segment is Bank. The Bank's activities include attracting deposits, offering banking services, and originating and purchasing single-family, multi-family, commercial real estate, construction, and other mortgage loans and, to a lesser extent, commercial business and consumer loans held for investment.